Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis in Low Disease Activity and Remission
Status:
Terminated
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
To investigate whether a reduced-dose dosing regimen (1x500mg semiannually) of rituximab
(RTX) (Mabthera®) is non-inferior in patients with rheumatoid arthritis (RA) whose disease is
in persistent low disease activity (LDA) or clinical remission (REM) (pLDA/pREM) as compared
to the standard dosing regimen of 1x1000mg semi-annual infusions.